These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21114864)

  • 1. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
    Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
    Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.
    Lu Y; Yao HP; Wang MH
    J Exp Clin Cancer Res; 2008 Oct; 27(1):55. PubMed ID: 18950514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
    Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
    Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.
    Zhang K; Zhou YQ; Yao HP; Wang MH
    Int J Oncol; 2010 Jan; 36(1):255-64. PubMed ID: 19956854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
    Wang MH; Lao WF; Wang D; Luo YL; Yao HP
    Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
    Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
    Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines.
    Chen YQ; Zhou YQ; Angeloni D; Kurtz AL; Qiang XZ; Wang MH
    Exp Cell Res; 2000 Nov; 261(1):229-38. PubMed ID: 11082293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.
    Yao HP; Zhuang CM; Zhou YQ; Zeng JY; Zhang RW; Wang MH
    Curr Cancer Drug Targets; 2013 Jul; 13(6):686-97. PubMed ID: 23597200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.
    Xu XM; Zhou YQ; Wang MH
    J Biol Chem; 2005 Jul; 280(26):25087-94. PubMed ID: 15878878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.
    Zhang K; Yao HP; Wang MH
    Carcinogenesis; 2008 Mar; 29(3):552-9. PubMed ID: 18204077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
    Lu Y; Yao HP; Wang MH
    Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
    Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
    Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity.
    Wei X; Hao L; Ni S; Liu Q; Xu J; Correll PH
    J Biol Chem; 2005 Dec; 280(48):40241-51. PubMed ID: 16166096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression.
    Bardella C; Costa B; Maggiora P; Patane' S; Olivero M; Ranzani GN; De Bortoli M; Comoglio PM; Di Renzo MF
    Cancer Res; 2004 Aug; 64(15):5154-61. PubMed ID: 15289319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
    Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
    Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant.
    Eckerich C; Schulte A; Martens T; Zapf S; Westphal M; Lamszus K
    J Neurochem; 2009 May; 109(4):969-80. PubMed ID: 19519771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.
    Wang D; Lao WF; Kuang YY; Geng SM; Mo LJ; He C
    Exp Cell Res; 2012 Dec; 318(20):2548-58. PubMed ID: 22975341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
    Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
    Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.
    Collesi C; Santoro MM; Gaudino G; Comoglio PM
    Mol Cell Biol; 1996 Oct; 16(10):5518-26. PubMed ID: 8816464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.